What's Happening?
A recent study has suggested a link between a discontinued hormone therapy, known as c-hGH, and a rare form of Alzheimer's disease. The treatment, which was derived from human corpses, was used between 1963 and 1985 to treat children with severe growth
hormone deficiency. Researchers from the UK National Prion Clinic have found that some individuals who received c-hGH are now showing signs of early-onset dementia, characterized by amyloid-beta plaques and tau tangles in the brain. These findings suggest the possibility of iatrogenic Alzheimer's disease, a form of the condition thought to result from medical transmission rather than aging or genetics. Despite skepticism from some researchers, the study authors advise clinicians to monitor cognitive changes in recipients of cadaveric human growth hormone.
Why It's Important?
The study raises concerns about the long-term effects of medical treatments that were once considered safe. The potential link between c-hGH and Alzheimer's disease highlights the importance of rigorous testing and monitoring of medical therapies, especially those involving biological materials. This research could lead to increased scrutiny of past medical practices and prompt further investigation into the safety of treatments derived from human tissues. The findings may also influence current medical protocols and encourage the development of synthetic alternatives to reduce the risk of disease transmission.
